Biotech

All Articles

Amgen records first phase 3 gain for $400M eczema medicine

.Amgen has actually shared (PDF) the very first stage 3 records on its $400 million eczema medicatio...

Biogen, UCB record stage 3 lupus succeed after failing earlier trial

.Biogen as well as UCB's rely on developing in to phase 3 on the back of a broken study looks to hav...

Aptadir hopes brand new RNA preventions may turn around challenging cancers

.Italian biotech Aptadir Therapeutics has actually released with the pledge that its pipeline of pre...

Wave surfs DMD effectiveness to regulators' doors, sending out stockpile

.Wave Life Sciences has actually satisfied its target in a Duchenne muscle dystrophy (DMD) research,...

Sanofi tweezes new CSO coming from in-stealth biotech

.After a handful of years in biotech, Mike Quigley, Ph.D., is actually coming back to the pharma fol...

Achilles drops tissue therapy system, supports for cutbacks after skipping 'office feasibility' goals

.Achilles Therapies has wrecked its own tactic. The British biotech is quiting working on its own cl...

Aligos trumpets phase 2 MASH gain, slashing liver excess fat approximately 46%

.Aligos Therapeutics is trumpeting a midstage win in metabolic-dysfunction affiliated steatohepatiti...

Basilea credit ratings $268M BARDA financing for antifungals, antibiotics

.Basilea Pharmaceutica's work developing new antifungals has obtained a notable improvement coming f...

Capricor sells Europe rights to late-stage DMD treatment for $35M

.Possessing actually scooped up the USA rights to Capricor Therapies' late-stage Duchenne muscular d...

FDA fragments adcomm for Applied's rare disease medicine

.After pushing back the selection meeting for Applied Therapeutics' metabolic ailment drug govoresta...